Michael Himonas – General Manager, Hellenic Association of Pharmaceutical Companies (SFEE), Member of the Board of Directors, EFPIA

Michael Himonas of SFEE, the umbrella pharmaceutical association of 40 global innovative biopharma companies and 20 local companies in Greece, explains how the country’s pharmaceutical clawback and rebate system is restricting the growth of the industry and ultimately limiting and delaying patient access to medicines. However, Himonas is also keen to note the advantages of Greece as an investment destination, citing big projects from Pfizer and Boehringer Ingelheim as case studies, noting the country’s world-class healthcare personnel, and adding that funding from the EU Recovery & Resilience Facility (RRF) is set to boost the digitalisation of Greek healthcare.  
Unlike other European countries which have capped their clawback system (Portugal) or replaced it with a discount scheme (Romania), the Greek clawback mechanism is out of control and unsustainable
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report